Managing Young Women with Breast Cancer
Logo
18 August, 2022

Grand Hyatt, Singapore

Hybrid Meeting

  • About Us
  • Welcome Message
  • Conference
    • 2022 Program At a Glance
    • 2022 Program
    • 2022 Speakers
  • 2021 Post Show Report
  • 2022 Partners
  • Registration
  • Contact Us
18 August, 2022

Grand Hyatt, Singapore

Hybrid Meeting

Quick Links  
Quick Links
  • 2021 Program
  • 2022 Speakers
  • Registration

2021 Program

Home 2021 Program

Event Day
12 August 2021

Young Women Forum 2021
Chairperson:

Rebecca Dent | Singapore

Rebecca
Rebecca Dent
Medical Oncologist | Singapore

Dr Rebecca Dent is Senior Consultant in the Department of Medical Oncology, National Cancer Centre Singapore and is Chief of the Breast Medical Oncology Service. She is also an Associate Professor at Duke-NUS Medical School. Dr Dent’s primary research interest is in the field of breast cancer, focusing on locally advanced breast cancer and triple-negative/basal-like breast cancers. She is principal investigator for several clinical trials for the treatment of preoperative and advanced breast cancer, and is a steering committee member for a number of large international trials

Sessions by this speaker
Thursday,

  -

Thursday,

  -

Thursday,

  -


The Neoadjuvant Therapy of TNBC – From Rags to Riches

Shani Paluch-Shimon | Israel

Shani
Shani Paluch-Shimon
Medical Oncologist | Israel

Dr Paluch-Shimon is a medical oncologist with a Masters in Epidemiology from the London School of Hygiene & Tropical Medicine. She is director of the Breast Oncology Program at Hadassah University Hospital in Jerusalem, which includes a dedicated service for the care and treatment of young women with breast cancer. Dr Paluch-Shimon was the first to establish dedicated services for young women in Israel. Her key areas of clinical interest and research are breast cancer in young women, BRCA-associated breast cancer, triple-negative breast cancer and neo-adjuvant therapies. She has co-authored over 60 scientific papers and has authored ESO-ESMO* international guidelines on breast cancer in young women, the ESMO clinical practice guidelines on screening and prevention of cancer in individuals with a hereditary breast and ovarian cancer syndrome. She is a member of the ESO-ESMO international consensus panel for the management of advanced breast cancer. Dr Paluch-Shimon is the subject editor for breast cancer guidelines for the ESMO clinical practice guidelines committee. Dr. Paluch-Shimon is currently a member of the ESMO Breast Faculty, a core faculty member in the European School of Oncology and co-chair of the European School of Oncology’s Breast Cancer in Young Women Conference. She is a graduate of the Talpiot physician leadership program (Sheba). She was a member of the Israeli Ministry of Health committee evaluating the national breast cancer screening policy and is a member of the Israeli National Cancer Council.

Lectures by this speaker
Thursday, 2021-08-12
The Neoadjuvant Therapy of TNBC – From Rags to Riches

  13:00 - 13:30

Thursday, 2021-08-12
Panel Discussion

  15:05 - 15:50

Thursday, 2021-08-12
Options for Fertility Preservation

  16:20 - 16:35

Thursday, 2021-08-12
Panel Discussion

  16:35 - 17:05

  17:00 - 17:30

Satellite Symposium - Novartis
Chairperson:

Andrea Wong | Singapore

Andrea
Andrea Wong
Senior Consultant, Department of Haematology-Oncology | Singapore

Dr Andrea Wong completed her undergraduate medical degree at the University of Glasgow, and obtained her postgraduate qualifications from the Royal College of Physicians, United Kingdom as well as the National University of Singapore. She specializes in breast and brain cancers and actively contributes to cancer research through her role as an investigator in several clinical trials conducted at the National University Cancer Institute, Singapore (NCIS). She is currently performing translational research work related to the development of novel targeted therapies for the treatment of advanced cancer in her capacity as an Adjunct Research Fellow at the Cancer Science Institute, Singapore. She has received multiple research grants for her work, including the Singapore National Medical Research Council Transition Award in 2018. In addition, she has authored several publications in peer-reviewed oncology and pharmacogenetics journals, and is a member of the Singapore Society of Oncology.

Sessions by this speaker
Thursday,

  -


Overall Survival in Young Women with HR+/HER2- aBC and the Clinical Implication of Intrinsic Subtypes

Lee Soo Chin | Singapore

Lee
Lee Soo Chin
Medical Oncologist | Singapore

She is currently Head and Senior Consultant in Medical Oncology and Associate Director of Research at the National University Cancer Institute, Singapore, and Senior Principal Investigator at the Cancer Science Institute, Singapore. She is ex-Chairperson of the Chapter of Medical Oncologists, Academy of Medicine, Singapore, and has been a member of the Ministry of Health Specialist Accreditation Board for Medical Oncology since 2009. She has been Chair of the National Healthcare Group Domain-Specific Ethics Review Board B since 2008. She is also a member of the Singapore Ministry of Health Drug Advisory Committee for Oncology drugs. She specialises in breast cancer and directs the Cancer Genetics program at the National University Cancer Institute, Singapore. Her research focus is on breast cancer, pharmacogenetics and cancer genetics, and she has been the Principal Investigator of more than 40 industry-sponsored and investigator-initiated breast cancer clinical trials. She directs the Haematology-Oncology Research Group, a cancer clinical trials unit that conducts 100-120 phase I-III therapeutics clinical trials in solid tumours and haematological malignancies at the National University Cancer Institute.

Lectures by this speaker
Thursday, 2021-08-12
Overall Survival in Young Women with HR+/HER2- aBC and the Clinical Implication of Intrinsic Subtypes

  13:30 - 14:00

Thursday, 2021-08-12
Genomic Tests in Young Women

  16:05 - 16:20

Thursday, 2021-08-12
Panel Discussion

  16:35 - 17:05

  17:30 - 18:00

Welcome Note
Speaker:

Rebecca Dent | Singapore

Rebecca
Rebecca Dent
Medical Oncologist | Singapore

Dr Rebecca Dent is Senior Consultant in the Department of Medical Oncology, National Cancer Centre Singapore and is Chief of the Breast Medical Oncology Service. She is also an Associate Professor at Duke-NUS Medical School. Dr Dent’s primary research interest is in the field of breast cancer, focusing on locally advanced breast cancer and triple-negative/basal-like breast cancers. She is principal investigator for several clinical trials for the treatment of preoperative and advanced breast cancer, and is a steering committee member for a number of large international trials

Sessions by this speaker
Thursday,

  -

Thursday,

  -

Thursday,

  -


Session 1: Diagnosing a Young Woman with Breast Cancer
Chairperson:

Rebecca Dent | Singapore

Rebecca
Rebecca Dent
Medical Oncologist | Singapore

Dr Rebecca Dent is Senior Consultant in the Department of Medical Oncology, National Cancer Centre Singapore and is Chief of the Breast Medical Oncology Service. She is also an Associate Professor at Duke-NUS Medical School. Dr Dent’s primary research interest is in the field of breast cancer, focusing on locally advanced breast cancer and triple-negative/basal-like breast cancers. She is principal investigator for several clinical trials for the treatment of preoperative and advanced breast cancer, and is a steering committee member for a number of large international trials

Sessions by this speaker
Thursday,

  -

Thursday,

  -

Thursday,

  -


Chairperson:

Faye Lim | Singapore

Faye
Faye Lim
Senior Consultant | Singapore

Dr Faye Lim graduated from the University of Nottingham Medical school and completed her Clinical Oncology Training at Mount Vernon Cancer Centre and University College Hospital. She is a senior consultant in the department of radiation oncology at the National Cancer Centre Singapore Her sub specialty includes breast and gastrointestinal cancers. She has a particular interest in the use of proton therapy in the treatment of breast cancer.

Sessions by this speaker
Thursday,

  -


Overview on Young Women with Breast Cancer

Anne Partridge | USA

Anne
Anne Partridge
Medical Oncologist | USA

Ann Partridge, MD, MPH is a Professor of Medicine at Harvard Medical School, and Vice Chair of Medical Oncology at Dana-Farber Cancer Institute, where she also serves as Director of the Adult Survivorship Program and leads the Program for Young Women with Breast Cancer. As a medical oncologist and clinical researcher, she has sought to improve the care and outcomes of patients with cancer by conducting research, and by developing innovative clinical programming. Dr. Partridge serves in leadership roles nationally and internationally including as co-chair of the Breast Committee of the Alliance for Clinical Trials in Oncology and co-chair of the biennial ESMO-ESO sponsored Breast Cancer in Young Women Conference. She also served as Chair of the Center for Disease Control and Prevention (CDC) Advisory Committee on Breast Cancer in Young Women from 2010-17. She has received prior awards and grants including a Champions of Change award from the White House, an ASCO Improving Cancer Care Grant, the CDC Carol Friedman Award, the American Association for Cancer Research (AACR) Outstanding Investigator Award for Breast Cancer, and the Ellen L. Stovall Award in Cancer Survivorship from ASCO, and the A. Clifford Barger Excellence in Mentoring Award from Harvard Medical School. After graduating from Georgetown University, Dr. Partridge received her medical degree from Cornell University Medical College, pursued an internal medicine residency at the Hospital for the University of Pennsylvania, and completed Medical Oncology and Hematology fellowship at Dana-Farber/Partners CancerCare. She earned a Master of Public Health degree at the Harvard School of Public Health.

Lectures by this speaker
Thursday, 2021-08-12
Overview on Young Women with Breast Cancer

  14:05 - 14:20

Thursday, 2021-08-12
Panel Discussion

  15:05 - 15:50

  18:05 - 18:20

What Are the Unique Challenges Faced by Young Women with Breast Cancer in Asia?

Nirmala Bhoo Pathy | Malaysia

Nirmala
Nirmala Bhoo Pathy
Clinical Epidemiologist | Malaysia

Nirmala Bhoo-Pathy works as an Associate Professor of Epidemiology in the Department of Social and Preventive Medicine, Faculty of Medicine, University of Malaya, and practices as a public health physician in University Malaya Medical Centre, Malaysia. She is also a visiting scholar at Queen’s University Belfast, United Kingdom since 2014. Dr Bhoo Pathy’s career is focused on optimizing life after cancer in resourcelimited settings through research and advocacy. She is particularly interested in the state of cancer control in the low- and middle-income countries, and enhancing treatment outcomes and patient-centered outcomes in these settings. Notably, Dr Bhoo Pathy was the principal investigator of phase III of the Asean CosTs In ONcology (ACTION) study, comprising close to 10,000 cancer patients from eight low-and middle-income member countries of the Association of South East Asian Nation (ASEAN). The study has been crucial in providing countryspecific evidence for Southeast Asian nations to prioritize policies and develop local solutions to reduce the financial loss and premature deaths associated with cancer. Dr Bhoo-Pathy currently serves in two Lancet Commissions, namely the Lancet Commission on Women and Cancer, and the Lancet Commission on Cancer and Health Systems. Besides her involvement in these commissions, she is a member of the Covid-19 and Cancer Taskforce, a globally representative group of cancer leaders who are gravely concerned that decisions made under the duress of the pandemic will have momentous consequences for cancer mortality for years to come https://covidcancertaskforce.org/ Nirmala Bhoo Pathy graduated as a medical doctor from University of Malaya, Malaysia in 2001. Following completion of her master’s degree in Public Health with distinction in 2008, she was awarded a fellowship by the European Commission, under which she completed a master’s degree in clinical epidemiology with cum laude, followed by a PhD (cancer epidemiology) from University of Utrecht, Netherlands in 2011.

Lectures by this speaker
Thursday, 2021-08-12
What Are the Unique Challenges Faced by Young Women with Breast Cancer in Asia?

  14:20 - 14:35

  18:20 - 18:35

What is the Role of MRI Screening in Young Woman with Breast Cancer?

Ellen Warner | Canada

Ellen
Ellen Warner
Medical Oncologist | Canada

Dr. Ellen Warner is a medical oncologist at the Odette Cancer Centre of Sunnybrook Health Sciences Centre and a Professor of Medicine at the University of Toronto. She also holds a Masters degree in clinical epidemiology. Her clinical practice and research are entirely devoted to the management of women living with breast cancer or at high risk for developing the disease. Her main research interests are identification and screening of high risk women, management of breast cancer in very young women, and lifestyle factors that affect breast cancer recurrence and/or quality of life. Dr. Warner’s research led to the establishment of the Ontario Breast Screening Program’s High Risk program that offers annual MRI and mammography to women across Ontario at very high risk for developing breast cancer. She is also founder and director of Sunnybrook’s PYNK: Breast Cancer Program for Young – a clinical, research and educational program for women diagnosed with breast cancer at age 40 or younger.

Lectures by this speaker
Thursday, 2021-08-12
What is the Role of MRI Screening in Young Woman with Breast Cancer?

  14:35 - 14:50

Thursday, 2021-08-12
Panel Discussion

  15:05 - 15:50

  18:35 - 18:50

Question & Answers

  18:50 - 19:05

Session 2: Challenging Cases in Young Women with Breast Cancer
Chairperson:

Shaheenah Dawood | United Arab Emirates

Shaheenah
Shaheenah Dawood
Medical Oncologist | United Arab Emirates

Dr. Shaheenah Dawood is a Consultant medical oncologist and associate professor in clinical oncology in the United Arab Emirates. She trained in medical oncology at McGill University Hospitals in Canada and subspecialized in breast cancer management at MD Anderson Cancer Center. During her training she was awarded multiple scholar in training awards and ASCO merit awards. She has served as an editorial fellow at the New England Journal of medicine and has an MPH from the Harvard School of Public Health. She has over 100 papers to her credit including 50 peer review original articles, 30 review articles and 12 book chapters. She serves as a reviewer for multiple journals including the Journal of Clinical Oncology. She currently leads the oncology clinical trials program at Mediclinic City Hospital Dubai. She also serves as president of the excellence In Oncology Care Congress that is held annually in Dubai and is co-president of the Asia pacific breast cancer summit (ABCS) and Asia pacific gastrointestinal cancer summit (APGCS). She has also recently launched the international BRCA forum and MENA immune-oncology summit.

Sessions by this speaker
Thursday,

  -

Lectures by this speaker
Thursday,

  -


Panel Discussion

Tira Tan | Singapore

Tira
Tira Tan
Consultant Medical Oncologist | Singapore

Dr Tira Tan is a consultant medical oncologist at the National Cancer Centre Singapore with a clinical focus in the treatment of breast cancers and early phase drug development. Dr Tan chairs the pre-operative and young women’s breast cancer programs at NCCS and is the primary and co-investigator on many early and late phase studies specifically in novel therapeutics and treatment strategies in triple negative breast cancer.

Sessions by this speaker
Thursday, 2021-08-12
Session 3: Managing a Young Woman with Adjuvant Therapy

  15:50 - 17:10

Lectures by this speaker
Thursday, 2021-08-12
Panel Discussion

  15:05 - 15:50

Elaine Lim | Singapore

Elaine
Elaine Lim
Senior Consultant | Singapore

Dr Elaine Lim is Senior Consultant, Division of Medical Oncology at the National Cancer Centre, Singapore. Her interests are centred on breast, gynaecological and lung cancers. After graduating from Trinity College, University of Cambridge, Dr. Lim was selected to join the Cambridge MBBCh-PhD programme. Her PhD dissertation on molecular genetics was supervised by Nobel Laureate, Professor Sydney Brenner and Professor Timothy Cox. After completing her clinical training in Cambridge, Dr. Lim worked in London, which included the Royal London Hospital and the prestigious London ‘golden circuit’ of Hammersmith Hospital and Royal Brompton Hospital. Upon her return to Singapore, she joined the National University of Singapore (NUS) and National University Hospital (NUH) to pursue a career in Medical Oncology. She later moved to Johns Hopkins Singapore as Consultant in Medical Oncology, as well as being Visiting Consultant at Tan Tock Seng Hospital (TTSH) and Kandang Kerbau Women’s and Children’s Hospital (KKH). After a few years in private practice with Singapore Oncology Consultants, she joined the National Cancer Centre, Singapore, Division of Medical Oncology. She has continued her laboratory research activities in collaboration with the Genome Institute of Singapore and the Institute of Molecular and Cell Biology, and actively participates in clinical trials.

Lectures by this speaker
Thursday, 2021-08-12
Panel Discussion

  15:05 - 15:50

Kim Hee-Jeong | Korea South

Kim
Kim Hee-Jeong
Associate Professor | Korea South

.

Lectures by this speaker
Thursday, 2021-08-12
Panel Discussion

  15:05 - 15:50

Anne Partridge | USA

Anne
Anne Partridge
Medical Oncologist | USA

Ann Partridge, MD, MPH is a Professor of Medicine at Harvard Medical School, and Vice Chair of Medical Oncology at Dana-Farber Cancer Institute, where she also serves as Director of the Adult Survivorship Program and leads the Program for Young Women with Breast Cancer. As a medical oncologist and clinical researcher, she has sought to improve the care and outcomes of patients with cancer by conducting research, and by developing innovative clinical programming. Dr. Partridge serves in leadership roles nationally and internationally including as co-chair of the Breast Committee of the Alliance for Clinical Trials in Oncology and co-chair of the biennial ESMO-ESO sponsored Breast Cancer in Young Women Conference. She also served as Chair of the Center for Disease Control and Prevention (CDC) Advisory Committee on Breast Cancer in Young Women from 2010-17. She has received prior awards and grants including a Champions of Change award from the White House, an ASCO Improving Cancer Care Grant, the CDC Carol Friedman Award, the American Association for Cancer Research (AACR) Outstanding Investigator Award for Breast Cancer, and the Ellen L. Stovall Award in Cancer Survivorship from ASCO, and the A. Clifford Barger Excellence in Mentoring Award from Harvard Medical School. After graduating from Georgetown University, Dr. Partridge received her medical degree from Cornell University Medical College, pursued an internal medicine residency at the Hospital for the University of Pennsylvania, and completed Medical Oncology and Hematology fellowship at Dana-Farber/Partners CancerCare. She earned a Master of Public Health degree at the Harvard School of Public Health.

Lectures by this speaker
Thursday, 2021-08-12
Overview on Young Women with Breast Cancer

  14:05 - 14:20

Thursday, 2021-08-12
Panel Discussion

  15:05 - 15:50

Ellen Warner | Canada

Ellen
Ellen Warner
Medical Oncologist | Canada

Dr. Ellen Warner is a medical oncologist at the Odette Cancer Centre of Sunnybrook Health Sciences Centre and a Professor of Medicine at the University of Toronto. She also holds a Masters degree in clinical epidemiology. Her clinical practice and research are entirely devoted to the management of women living with breast cancer or at high risk for developing the disease. Her main research interests are identification and screening of high risk women, management of breast cancer in very young women, and lifestyle factors that affect breast cancer recurrence and/or quality of life. Dr. Warner’s research led to the establishment of the Ontario Breast Screening Program’s High Risk program that offers annual MRI and mammography to women across Ontario at very high risk for developing breast cancer. She is also founder and director of Sunnybrook’s PYNK: Breast Cancer Program for Young – a clinical, research and educational program for women diagnosed with breast cancer at age 40 or younger.

Lectures by this speaker
Thursday, 2021-08-12
What is the Role of MRI Screening in Young Woman with Breast Cancer?

  14:35 - 14:50

Thursday, 2021-08-12
Panel Discussion

  15:05 - 15:50

Shani Paluch-Shimon | Israel

Shani
Shani Paluch-Shimon
Medical Oncologist | Israel

Dr Paluch-Shimon is a medical oncologist with a Masters in Epidemiology from the London School of Hygiene & Tropical Medicine. She is director of the Breast Oncology Program at Hadassah University Hospital in Jerusalem, which includes a dedicated service for the care and treatment of young women with breast cancer. Dr Paluch-Shimon was the first to establish dedicated services for young women in Israel. Her key areas of clinical interest and research are breast cancer in young women, BRCA-associated breast cancer, triple-negative breast cancer and neo-adjuvant therapies. She has co-authored over 60 scientific papers and has authored ESO-ESMO* international guidelines on breast cancer in young women, the ESMO clinical practice guidelines on screening and prevention of cancer in individuals with a hereditary breast and ovarian cancer syndrome. She is a member of the ESO-ESMO international consensus panel for the management of advanced breast cancer. Dr Paluch-Shimon is the subject editor for breast cancer guidelines for the ESMO clinical practice guidelines committee. Dr. Paluch-Shimon is currently a member of the ESMO Breast Faculty, a core faculty member in the European School of Oncology and co-chair of the European School of Oncology’s Breast Cancer in Young Women Conference. She is a graduate of the Talpiot physician leadership program (Sheba). She was a member of the Israeli Ministry of Health committee evaluating the national breast cancer screening policy and is a member of the Israeli National Cancer Council.

Lectures by this speaker
Thursday, 2021-08-12
The Neoadjuvant Therapy of TNBC – From Rags to Riches

  13:00 - 13:30

Thursday, 2021-08-12
Panel Discussion

  15:05 - 15:50

Thursday, 2021-08-12
Options for Fertility Preservation

  16:20 - 16:35

Thursday, 2021-08-12
Panel Discussion

  16:35 - 17:05

  19:05 - 19:50

Session 3: Managing a Young Woman with Adjuvant Therapy
Chairperson:

Tira Tan | Singapore

Tira
Tira Tan
Consultant Medical Oncologist | Singapore

Dr Tira Tan is a consultant medical oncologist at the National Cancer Centre Singapore with a clinical focus in the treatment of breast cancers and early phase drug development. Dr Tan chairs the pre-operative and young women’s breast cancer programs at NCCS and is the primary and co-investigator on many early and late phase studies specifically in novel therapeutics and treatment strategies in triple negative breast cancer.

Sessions by this speaker
Thursday,

  -

Lectures by this speaker
Thursday,

  -


Chairperson:

Veronique Tan | Singapore

Veronique
Veronique Tan
Head & Senior Consultant | Singapore

Clinical Associate Professor Veronique Tan is a Senior Consultant and Chief of Breast Surgery at National Cancer Centre Singapore and Singapore General Hospital. She also Heads the SingHealth Duke-NUS Breast Centre. As one of the few breast surgeons in Singapore formally trained in oncoplastic breast surgery, A/Prof Tan believes that the appearance of the breast after cancer resection is important, and that every patient should have a tailored, individualised surgical solution. She works within a dynamic multidisciplinary team to deliver precise, high quality and effective treatment. A/Prof Tan’s practice covers benign breast conditions, the diagnosis and surgical treatment of symptomatic and screen-detected breast cancer, oncoplastic breast surgery and breast reconstruction. Active in research and teaching, A/Prof Tan has published numerous articles in peer-reviewed journals and contributed several book chapters on oncoplastic and reconstructive breast surgery.

Sessions by this speaker
Thursday,

  -


Optimal Endocrine Therapy and Duration of Therapy?

Matteo Lambertini | Italy

Matteo
Matteo Lambertini
Medical Oncologist | Italy

Matteo Lambertini is adjunct professor and consultant in medical oncology at the IRCCS Policlinico San Martino Hospital – University of Genova in Genova (Italy). He is mainly focused in the care of breast cancer patients and is deeply involved in breast cancer research. Above all, he has a particular expertise in the management of breast cancer in young women, with a specific attention to the fertility and pregnancy-related issues that they have to face after diagnosis. During his medical oncology training, he had the opportunity to work and collaborate with several national and international leading experts in the field; these experiences have played a crucial role to deepen his skills in the management of breast cancer in young women. Thanks to the support of the European Society for Medical Oncology (ESMO), he has recently completed his PhD at the Universite Libre de Bruxelles (U.L.B.) in Brussels (Belgium) with a project entitled “Unmet Fertility and Pregnancy-related Issues in Young Breast Cancer Patients.” With this work, he has contributed to improve our understanding of many controversial aspects related to the management of breast cancer in young women specifically focusing on fertility preservation and the possibility to have a pregnancy following treatment completion, with the ultimate goal to further improve the care and quality of life of these young women. He is member of the guideline group on fertility preservation in cancer patients for the European Society for Medical Oncology (ESMO), the European Society of Human Reproduction and Embriology (ESHRE) and the Italian Association of Medical Oncology (AIOM). He has authored several publications in peer-reviewed journals and book chapters in the field of breast cancer in young women. His most important research conducted so far addressed the role of administering gonadotropin-releasing hormone (GnRH) analogs during chemotherapy as a strategy to preserve ovarian function and fertility in early breast cancer patients who are candidates to receive cytotoxic therapy, the safety of having a pregnancy in women with prior history of breast cancer, and the impact of carrying a germline BRCA mutation on patients’ fertility and pregnancy-related issues.

Lectures by this speaker
Thursday, 2021-08-12
Optimal Endocrine Therapy and Duration of Therapy?

  15:50 - 16:05

Thursday, 2021-08-12
Panel Discussion

  16:35 - 17:05

  19:50 - 20:05

Genomic Tests in Young Women

Lee Soo Chin | Singapore

Lee
Lee Soo Chin
Medical Oncologist | Singapore

She is currently Head and Senior Consultant in Medical Oncology and Associate Director of Research at the National University Cancer Institute, Singapore, and Senior Principal Investigator at the Cancer Science Institute, Singapore. She is ex-Chairperson of the Chapter of Medical Oncologists, Academy of Medicine, Singapore, and has been a member of the Ministry of Health Specialist Accreditation Board for Medical Oncology since 2009. She has been Chair of the National Healthcare Group Domain-Specific Ethics Review Board B since 2008. She is also a member of the Singapore Ministry of Health Drug Advisory Committee for Oncology drugs. She specialises in breast cancer and directs the Cancer Genetics program at the National University Cancer Institute, Singapore. Her research focus is on breast cancer, pharmacogenetics and cancer genetics, and she has been the Principal Investigator of more than 40 industry-sponsored and investigator-initiated breast cancer clinical trials. She directs the Haematology-Oncology Research Group, a cancer clinical trials unit that conducts 100-120 phase I-III therapeutics clinical trials in solid tumours and haematological malignancies at the National University Cancer Institute.

Lectures by this speaker
Thursday, 2021-08-12
Overall Survival in Young Women with HR+/HER2- aBC and the Clinical Implication of Intrinsic Subtypes

  13:30 - 14:00

Thursday, 2021-08-12
Genomic Tests in Young Women

  16:05 - 16:20

Thursday, 2021-08-12
Panel Discussion

  16:35 - 17:05

  20:05 - 20:20

Options for Fertility Preservation

Shani Paluch-Shimon | Israel

Shani
Shani Paluch-Shimon
Medical Oncologist | Israel

Dr Paluch-Shimon is a medical oncologist with a Masters in Epidemiology from the London School of Hygiene & Tropical Medicine. She is director of the Breast Oncology Program at Hadassah University Hospital in Jerusalem, which includes a dedicated service for the care and treatment of young women with breast cancer. Dr Paluch-Shimon was the first to establish dedicated services for young women in Israel. Her key areas of clinical interest and research are breast cancer in young women, BRCA-associated breast cancer, triple-negative breast cancer and neo-adjuvant therapies. She has co-authored over 60 scientific papers and has authored ESO-ESMO* international guidelines on breast cancer in young women, the ESMO clinical practice guidelines on screening and prevention of cancer in individuals with a hereditary breast and ovarian cancer syndrome. She is a member of the ESO-ESMO international consensus panel for the management of advanced breast cancer. Dr Paluch-Shimon is the subject editor for breast cancer guidelines for the ESMO clinical practice guidelines committee. Dr. Paluch-Shimon is currently a member of the ESMO Breast Faculty, a core faculty member in the European School of Oncology and co-chair of the European School of Oncology’s Breast Cancer in Young Women Conference. She is a graduate of the Talpiot physician leadership program (Sheba). She was a member of the Israeli Ministry of Health committee evaluating the national breast cancer screening policy and is a member of the Israeli National Cancer Council.

Lectures by this speaker
Thursday, 2021-08-12
The Neoadjuvant Therapy of TNBC – From Rags to Riches

  13:00 - 13:30

Thursday, 2021-08-12
Panel Discussion

  15:05 - 15:50

Thursday, 2021-08-12
Options for Fertility Preservation

  16:20 - 16:35

Thursday, 2021-08-12
Panel Discussion

  16:35 - 17:05

  20:20 - 20:35

Panel Discussion

Lee Soo Chin | Singapore

Lee
Lee Soo Chin
Medical Oncologist | Singapore

She is currently Head and Senior Consultant in Medical Oncology and Associate Director of Research at the National University Cancer Institute, Singapore, and Senior Principal Investigator at the Cancer Science Institute, Singapore. She is ex-Chairperson of the Chapter of Medical Oncologists, Academy of Medicine, Singapore, and has been a member of the Ministry of Health Specialist Accreditation Board for Medical Oncology since 2009. She has been Chair of the National Healthcare Group Domain-Specific Ethics Review Board B since 2008. She is also a member of the Singapore Ministry of Health Drug Advisory Committee for Oncology drugs. She specialises in breast cancer and directs the Cancer Genetics program at the National University Cancer Institute, Singapore. Her research focus is on breast cancer, pharmacogenetics and cancer genetics, and she has been the Principal Investigator of more than 40 industry-sponsored and investigator-initiated breast cancer clinical trials. She directs the Haematology-Oncology Research Group, a cancer clinical trials unit that conducts 100-120 phase I-III therapeutics clinical trials in solid tumours and haematological malignancies at the National University Cancer Institute.

Lectures by this speaker
Thursday, 2021-08-12
Overall Survival in Young Women with HR+/HER2- aBC and the Clinical Implication of Intrinsic Subtypes

  13:30 - 14:00

Thursday, 2021-08-12
Genomic Tests in Young Women

  16:05 - 16:20

Thursday, 2021-08-12
Panel Discussion

  16:35 - 17:05

Matteo Lambertini | Italy

Matteo
Matteo Lambertini
Medical Oncologist | Italy

Matteo Lambertini is adjunct professor and consultant in medical oncology at the IRCCS Policlinico San Martino Hospital – University of Genova in Genova (Italy). He is mainly focused in the care of breast cancer patients and is deeply involved in breast cancer research. Above all, he has a particular expertise in the management of breast cancer in young women, with a specific attention to the fertility and pregnancy-related issues that they have to face after diagnosis. During his medical oncology training, he had the opportunity to work and collaborate with several national and international leading experts in the field; these experiences have played a crucial role to deepen his skills in the management of breast cancer in young women. Thanks to the support of the European Society for Medical Oncology (ESMO), he has recently completed his PhD at the Universite Libre de Bruxelles (U.L.B.) in Brussels (Belgium) with a project entitled “Unmet Fertility and Pregnancy-related Issues in Young Breast Cancer Patients.” With this work, he has contributed to improve our understanding of many controversial aspects related to the management of breast cancer in young women specifically focusing on fertility preservation and the possibility to have a pregnancy following treatment completion, with the ultimate goal to further improve the care and quality of life of these young women. He is member of the guideline group on fertility preservation in cancer patients for the European Society for Medical Oncology (ESMO), the European Society of Human Reproduction and Embriology (ESHRE) and the Italian Association of Medical Oncology (AIOM). He has authored several publications in peer-reviewed journals and book chapters in the field of breast cancer in young women. His most important research conducted so far addressed the role of administering gonadotropin-releasing hormone (GnRH) analogs during chemotherapy as a strategy to preserve ovarian function and fertility in early breast cancer patients who are candidates to receive cytotoxic therapy, the safety of having a pregnancy in women with prior history of breast cancer, and the impact of carrying a germline BRCA mutation on patients’ fertility and pregnancy-related issues.

Lectures by this speaker
Thursday, 2021-08-12
Optimal Endocrine Therapy and Duration of Therapy?

  15:50 - 16:05

Thursday, 2021-08-12
Panel Discussion

  16:35 - 17:05

Shani Paluch-Shimon | Israel

Shani
Shani Paluch-Shimon
Medical Oncologist | Israel

Dr Paluch-Shimon is a medical oncologist with a Masters in Epidemiology from the London School of Hygiene & Tropical Medicine. She is director of the Breast Oncology Program at Hadassah University Hospital in Jerusalem, which includes a dedicated service for the care and treatment of young women with breast cancer. Dr Paluch-Shimon was the first to establish dedicated services for young women in Israel. Her key areas of clinical interest and research are breast cancer in young women, BRCA-associated breast cancer, triple-negative breast cancer and neo-adjuvant therapies. She has co-authored over 60 scientific papers and has authored ESO-ESMO* international guidelines on breast cancer in young women, the ESMO clinical practice guidelines on screening and prevention of cancer in individuals with a hereditary breast and ovarian cancer syndrome. She is a member of the ESO-ESMO international consensus panel for the management of advanced breast cancer. Dr Paluch-Shimon is the subject editor for breast cancer guidelines for the ESMO clinical practice guidelines committee. Dr. Paluch-Shimon is currently a member of the ESMO Breast Faculty, a core faculty member in the European School of Oncology and co-chair of the European School of Oncology’s Breast Cancer in Young Women Conference. She is a graduate of the Talpiot physician leadership program (Sheba). She was a member of the Israeli Ministry of Health committee evaluating the national breast cancer screening policy and is a member of the Israeli National Cancer Council.

Lectures by this speaker
Thursday, 2021-08-12
The Neoadjuvant Therapy of TNBC – From Rags to Riches

  13:00 - 13:30

Thursday, 2021-08-12
Panel Discussion

  15:05 - 15:50

Thursday, 2021-08-12
Options for Fertility Preservation

  16:20 - 16:35

Thursday, 2021-08-12
Panel Discussion

  16:35 - 17:05

Yap Yoon Sim | Singapore

Yap
Yap Yoon Sim
Medical Oncologist | Singapore

Dr. Yap is Senior Consultant in the Division of Medical Oncology at the National Cancer Centre Singapore, and Associate Professor at Duke-NUS Medical School. Dr. Yap obtained her undergraduate and postgraduate medical degrees from the University of Adelaide in Australia. She is a fellow of the Royal Australasian College of Physicians. Upon completion of her specialist training in medical oncology in Australia, she undertook a research fellowship with the Breast Unit at the Royal Marsden Hospital, London, before relocating to National Cancer Centre Singapore. A recipient of the Singapore National Medical Research Council (NMRC) Clinician Scientist Award (CSA), her research focuses primarily on clinical and translational research in breast cancer, including liquid biopsies and predictive biomarkers, development of novel therapeutic strategies, and epidemiologic studies on treatment outcomes in breast cancer. She is the principal investigator of several phase 1 to 3 clinical trials for various compounds such as CDK inhibitors, PI3K and mTOR inhibitors, selective estrogen receptor degraders, HER2-targeting agents and immunotherapy, in addition to investigator-initiated studies.

Lectures by this speaker
Thursday, 2021-08-12
Panel Discussion

  16:35 - 17:05

  20:35 - 21:05

Closing Remarks

Shaheenah Dawood | United Arab Emirates

Shaheenah
Shaheenah Dawood
Medical Oncologist | United Arab Emirates

Dr. Shaheenah Dawood is a Consultant medical oncologist and associate professor in clinical oncology in the United Arab Emirates. She trained in medical oncology at McGill University Hospitals in Canada and subspecialized in breast cancer management at MD Anderson Cancer Center. During her training she was awarded multiple scholar in training awards and ASCO merit awards. She has served as an editorial fellow at the New England Journal of medicine and has an MPH from the Harvard School of Public Health. She has over 100 papers to her credit including 50 peer review original articles, 30 review articles and 12 book chapters. She serves as a reviewer for multiple journals including the Journal of Clinical Oncology. She currently leads the oncology clinical trials program at Mediclinic City Hospital Dubai. She also serves as president of the excellence In Oncology Care Congress that is held annually in Dubai and is co-president of the Asia pacific breast cancer summit (ABCS) and Asia pacific gastrointestinal cancer summit (APGCS). She has also recently launched the international BRCA forum and MENA immune-oncology summit.

Sessions by this speaker
Thursday, 2021-08-12
Session 2: Challenging Cases in Young Women with Breast Cancer

  15:05 - 15:50

Lectures by this speaker
Thursday, 2021-08-12
Closing Remarks

  17:05 - 17:10

  21:05 - 21:10


Organised By :
INDEX Conferences & Exhibitions Org. Est.
INDEX Conferences & Exhibitions Org. Est.

COPYRIGHT © 2022. ALL RIGHTS RESERVED.